WebSep 12, 2024 · BioVie, Inc. is a biopharmaceutical company, which discovers, develops and commercializes drug therapies for liver disease. It focuses on BIV201, which treats ascites due to chronic liver ... WebThe Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...
Stock Screener: Search and Filter Stocks — TradingView
WebPrice target. 10.33 0.00 0.00%. The 3 analysts offering 1 year price forecasts for BIVI have a max estimate of — and a min estimate of —. WebApplications, once judged impossible, can now be accomplished with the bivi-TEC® Screen. The bivi-TEC® proves to be the best machine for screening: Wood; Carpet; Aggregate; … therons body shop
BIOVIE INC. : Technical Analysis Chart BIVI US09074F2074 ...
WebBiovie Inc. (BIVI) The Moving Average is the average price of the security or contact for the Period shown. For example, a 9-period moving average is the average of the closing prices for the past 9 periods, including the current period. For intraday data the current price is used in place of the closing price. WebApr 6, 2024 · BioVie rises 21% on FDA nod to start phase 2 trial of NE3107 in Parkinson’s Disease. SA NewsTue, Oct. 26, 2024. WebBioVie Inc (NASDAQ:BIVI) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the ... theron scienceworcs ag